Anthraquinone-2-carboxylic acid

Synonyms: 蒽醌-2-羧酸
Anthraquinone-2-carboxylic acid 是一种具有口服活性的蒽醌化合物和抗菌 (Antibacterial) 剂,可从 Bajitian 中分离得到,能抑制 DPP-IV、COX-2、NF-κB 和 AP-1 的激活,阻止 IAV 诱导的 RIG-I/STAT1 通路激活,缓解 IAV 介导的体重下降,抵御致命性 IAV 感染,并抑制多种葡萄球菌属 (Staphylococcus) 菌株的生长,具有强大的抗炎、免疫调节、镇痛和抗菌活性。
产品编号: MS-P19074 纯度: 98.0% CAS No.: 117-78-2 分子式: C15H8O4 分子量: 252.22
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
询价

产品描述

Anthraquinone-2-carboxylic acid 是一种具有口服活性的蒽醌化合物和抗菌 (Antibacterial) 剂,可从 Bajitian 中分离得到,能抑制 DPP-IV、COX-2、NF-κB 和 AP-1 的激活,阻止 IAV 诱导的 RIG-I/STAT1 通路激活,缓解 IAV 介导的体重下降,抵御致命性 IAV 感染,并抑制多种葡萄球菌属 (Staphylococcus) 菌株的生长,具有强大的抗炎、免疫调节、镇痛和抗菌活性。

生物实验数据

生物活性 Anthraquinone-2-carboxylic acid is an orally active anthraquinone compound and antibacterial agent that can be isolated from Bajitian, inhibits the activation of DPP-IV, COX-2, NF-κB, and AP-1, blocks IAV-induced RIG-I/STAT1 pathway activation, alleviates IAV-mediated body weight loss, protects against lethal IAV infection, and inhibits the growth of multiple Staphylococcus strains, possessing potent anti-inflammatory, immunomodulatory, analgesic, and antibacterial activities.
IC50 & Target

DPP-4

 

COX-2

 

STAT1

 

体外研究
(In Vitro)

Anthraquinone-2-carboxylic acid (50 μM; 6 h) 可强效抑制 RAW264.7 巨噬细胞中 LPS 诱导的 iNOS、TNF-α 和 COX-2 mRNA 的表达。
Anthraquinone-2-carboxylic acid (50 μM; 16 h) 可强效抑制 LPS 诱导的 RAW264.7 巨噬细胞中 COX-2 蛋白表达。
Anthraquinone-2-carboxylic acid (50 μM) 可强效抑制 HEK293 细胞中 PMA 诱导的 NF-κB 和 AP-1 启动子活性。
Anthraquinone-2-carboxylic acid (0.005-100 μM; 对于细胞毒性测试为 72 h) 可抑制四种不同流感病毒株在 MDCK 细胞中诱导的致细胞病变效应,其 EC50 值为 33.34 至 73.45 μM,且在浓度高达 100 μM 时无细胞毒性。
Anthraquinone-2-carboxylic acid (1.23-100 μM) 可剂量依赖性降低 MDCK 细胞中 H1N1 PR/8 的病毒 RNA 拷贝数和感染性颗粒产量,在 100 μM 时观察到最大抑制效果。
Anthraquinone-2-carboxylic acid (3.7-100 μM; 24 h) 可剂量依赖性降低 A549 细胞中 PB2、NP 和 NS1 蛋白的表达。
Anthraquinone-2-carboxylic acid (3.7-100 μM; 24 h) 可剂量依赖性地抑制 H1N1 PR/8 诱导的 A549 细胞中 RIG-I/STAT1 信号通路激活。
Anthraquinone-2-carboxylic acid (18 h) 可抑制多种葡萄球菌属 (Staphylococcus) 菌株的生长,对 S. epidermidis ATCC 12228 的 MIC 为 62.5 µg/mL,对 S. aureus ATCC 25923 和 S. epidermidis KCTC 13171 的 MIC 为 125 µg/mL,对 MRSA1、MRSA2 以及 S. saprophyticus ATCC 15305 的 MIC 为 250 µg/mL。
Anthraquinone-2-carboxylic acid (18 h) 可与氧化铜纳米颗粒协同作用于金黄色葡萄球菌 ATCC 25923,使其有效 MIC 从 125 µg/mL 降至 15.6 µg/mL,产生的 FICI 为 0.375。

Real Time qPCR

Cell Line: murine RAW264.7 macrophage cells (LPS-stimulated)
Concentration: 50 μM
Incubation Time: 6 h
Result: Significantly suppressed LPS-induced mRNA expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and cyclooxygenase-2 (COX-2), with statistically significant reductions (P < 0.01) compared to LPS-treated control cells.

Western Blot Analysis

Cell Line: murine RAW264.7 macrophage cells (LPS-stimulated)
Concentration: 25 μM, 50 μM
Incubation Time: 16 h
Result: Significantly reduced LPS-induced COX-2 protein levels (P < 0.01) compared to LPS-treated control cells at 50 μM.
Did not produce a statistically significant reduction of LPS-induced COX-2 protein levels at 25 μM.

Western Blot Analysis

Cell Line: A549 cells
Concentration: 3.7-100 μM
Incubation Time: 24 h
Result: Dose-dependently suppressed viral PB2, NP, and NS1 protein levels.
Reduced PB2 protein levels to ~20% of virus-only control levels at 100 μM.
Reduced NP protein levels to ~10% of virus-only control levels at 100 μM.
Reduced NS1 protein levels to ~30% of virus-only control levels at 100 μM.

Western Blot Analysis

Cell Line: A549 cells infected with H1N1 PR/8
Concentration: 3.7-100 μM
Incubation Time: 24 h
Result: Dose-dependently decreased virus-induced upregulation of MDA5, RIG-I, p-STAT1, STAT1, and TRIM25 protein levels.
Caused a non-statistically significant downward trend in MAVS protein levels.
体内研究
(In Vivo)

Anthraquinone-2-carboxylic acid (3-30 mg/kg;口服;1 天内每 8 小时给 1 次,共 3 次) 可使 HCl/EtOH 诱导的胃黏膜损伤减少,并抑制胃组织中的炎症信号传导及 COX-2 表达。
Anthraquinone-2-carboxylic acid (3-30 mg/kg;口服;阿司匹林给予前 30 分钟单次给予) 可使阿司匹林诱导的胃黏膜损伤减少,并抑制胃组织中的中性粒细胞浸润和炎症信号传导。
Anthraquinone-2-carboxylic acid (3-30 mg/kg;口服;每日;连续 7 天) 可显著减轻花生四烯酸诱导的小鼠耳肿胀。
Anthraquinone-2-carboxylic acid (30-60 mg/kg;口服;乙酸处理前 60 分钟单次给) 可使小鼠中乙酸诱导的腹部扭体反应分别减少。
Anthraquinone-2-carboxylic acid (10-100 mg/kg;灌胃;每日;连续 5 天) 可呈剂量依赖性保护 BALB/c 小鼠免受致死性甲型流感病毒感染,降低肺组织中的病毒载量,并减轻肺损伤及促炎细胞因子的产生。

Animal Model: ICR (male, 6 weeks old, HCl/EtOH-induced gastritis)
Dosage: 3 mg/kg; 30 mg/kg
Administration: p.o.; three times every 8 hours in one day
Result: Reduced HCl/EtOH-induced gastric mucosal erosive lesions by up to 73% at 30 mg/kg.
Significantly suppressed COX-2 mRNA expression in stomach tissue at both doses, with statistically significant reduction at 30 mg/kg relative to vehicle control.
Inhibited HCl/EtOH-induced phosphorylation of p38, Src, and Syk, and reduced degradation of IRAK1 in stomach tissue at both doses, with statistically significant effects at 30 mg/kg relative to vehicle control.
Animal Model: ICR (male, 6 weeks old, aspirin-induced gastritis)
Dosage: 3 mg/kg; 30 mg/kg
Administration: p.o.; single dose 30 minutes prior to aspirin
Result: Reduced aspirin-induced gastric mucosal erosive lesions by up to 78% at 30 mg/kg.
Significantly reduced MPO activity (a marker of neutrophil infiltration) in stomach tissue at both doses relative to vehicle control.
Reduced gastric mucosal damage observed via histopathology at 30 mg/kg.
Inhibited aspirin-induced degradation of IRAK1 in stomach tissue at both doses relative to vehicle control.
Animal Model: ICR (male, 6 weeks old, arachidonic acid-induced ear edema and nociception)
Dosage: 3 mg/kg; 30 mg/kg
Administration: p.o.; daily; 7 days
Result: Significantly reduced arachidonic acid-induced ear edema at both doses relative to vehicle control.
Animal Model: ICR (male, 6 weeks old, acetic acid-induced abdominal nociception)
Dosage: 3 mg/kg; 30 mg/kg; 60 mg/kg
Administration: p.o.; single dose 60 minutes prior to acetic acid
Result: Reduced acetic acid-induced abdominal writhes by 57% at 30 mg/kg relative to vehicle control.
Reduced acetic acid-induced abdominal writhes by 72% at 60 mg/kg relative to vehicle control.
Animal Model: BALB/c (female, 7 weeks old, 16-18 g, intranasal inoculation with 3×LD50 of H1N1 PR/8 strain)
Dosage: 100 mg/kg; 10 mg/kg
Administration: i.g.; daily; 5 days
Result: Rescued 60% of mice from lethal influenza A virus challenge, mitigated initial weight loss, and facilitated progressive body weight restoration.
Significantly reduced lung viral RNA copy numbers (p < 0.0001) and infectious viral particle titers (p < 0.05) at 2 days post infection.
Alleviated influenza-induced lung pathology (reduced vascular congestion, edema, necrosis, and inflammatory cell infiltration) and significantly decreased lung expression of pro-inflammatory cytokines IL-1β and IL-6 (p < 0.05).
Provided partial protection, with improved survival and reduced weight loss compared to vehicle controls, but with less pronounced effects than the 100 mg/kg dose.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 252.22
分子式 C15H8O4
CAS No. 117-78-2
别名 蒽醌-2-羧酸

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 3.96 mg/mL (15.70 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (99.12 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9648 mL19.8240 mL39.6479 mL99.1198 mL
5 mM0.7930 mL3.9648 mL7.9296 mL19.8240 mL
10 mM0.3965 mL1.9824 mL3.9648 mL9.9120 mL
15 mM0.2643 mL1.3216 mL2.6432 mL6.6080 mL
20 mM0.1982 mL0.9912 mL1.9824 mL4.9560 mL
25 mM0.1586 mL0.7930 mL1.5859 mL3.9648 mL
30 mM0.1322 mL0.6608 mL1.3216 mL3.3040 mL
40 mM0.0991 mL0.4956 mL0.9912 mL2.4780 mL
50 mM0.0793 mL0.3965 mL0.7930 mL1.9824 mL
60 mM0.0661 mL0.3304 mL0.6608 mL1.6520 mL
80 mM0.0496 mL0.2478 mL0.4956 mL1.2390 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础